23andMe Stock Price | ME Stock Quote, News, and History

Publish date: 2024-07-25

Feb. 04 2021 Mar. 05 2021

Download Reset

Loading..
DateOpenCloseDaily HighDaily Low

Price change over selected period: 0% 0

Total Analysts: 7

Buy Ratings: 5 Neutral Ratings: 2 Sell Ratings: 0

Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}

Price *Price Target

Lowest: 0.47 Median: 4.25 Highest: 7.00

All
 2024202520262027
Revenue-236276303
Dividend---0.00
Dividend Yield (in %)0.00 %0.00 %0.00 %0.00 %
EPS--0.61-0.56-0.49
P/E Ratio-0.38-0.63-0.68-0.78
EBIT--324-297-243
EBITDA--202-173-112
Net Profit--309-289-234
Net Profit Adjusted--309-289-234
Pre-Tax Profit--309-289-234
Net Profit (Adjusted)----
EPS (Non-GAAP) ex. SOE----
EPS (GAAP)----
Gross Income----
Cash Flow from Investing----
Cash Flow from Operations----
Cash Flow from Financing----
Cash Flow per Share----
Free Cash Flow----
Free Cash Flow per Share----
Book Value per Share----
Net Debt----
Research & Development Exp.----
Capital Expenditure----
Selling, General & Admin. Exp.----
Shareholder’s Equity----
Total Assets----
 Previous Quarter
ending 06/30/24
Current Quarter
ending 09/30/24
Next Quarter
ending 12/31/24
Current Year
ending 03/31/25
Next Year
ending 03/31/26
Earnings Estimates
No. of Analysts11122
Average Estimate-0.220 USD-0.139 USD-0.147 USD-0.610 USD-0.560 USD
Year Ago-0.226 USD-0.159 USD-0.578 USD-1.401 USD-
Publish Date8/8/202411/6/20242/5/2025--
Revenue Estimates
No. of Analysts22222
Average Estimate52 USD55 USD57 USD236 USD276 USD
Year Ago61 USD50 USD45 USD220 USD-
Publish Date8/8/202411/6/20242/5/2025--

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

DateNameDividend*yieldCurrency
202423andMe Holding Co Registered Shs -A-0.000.00USD
202323andMe Holding Co Registered Shs -A-0.000.00USD
202223andMe Holding Co Registered Shs -A-0.000.00USD
202123andMe Holding Co Registered Shs -A-0.000.00USD
202023andMe Holding Co Registered Shs -A-0.00-USD
201923andMe Holding Co Registered Shs -A---USD

*Yield of the Respective Date

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA. .

Ownerin %
Freefloat88.87
The Vanguard Group, Inc.6.97
Newview Capital Partners I LLC6.01
NewView Capital Management LLC6.01
Vanguard Group, Inc. (Subfiler)4.90
BlackRock Fund Advisors3.43
Euclidean Capital LLC3.17
Vanguard Total Stock Market ETF2.89
BlackRock Institutional Trust Co. NA2.45
Geode Capital Management LLC2.31
iShares Russell 2000 ETF2.22
Alphabet, Inc.2.08
Alphabet, Inc.2.08
State Street Corp.1.98
Sapphire Ventures LLC1.64

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcLnEZqqtp5Og